Tandem high-dose influenza vaccination is associated with more durable serologic immunity in patients with plasma cell dyscrasias
Branagan AR, Duffy E, Gan G, Li F, Foster C, Verma R, Zhang L, Parker TL, Seropian S, Cooper DL, Brandt D, Kortmansky J, Witt D, Ferencz TM, Dhodapkar KM, Dhodapkar MV. Tandem high-dose influenza vaccination is associated with more durable serologic immunity in patients with plasma cell dyscrasias. Blood Advances 2021, 5: 1535-1539. PMID: 33683337, PMCID: PMC7948269, DOI: 10.1182/bloodadvances.2020003880.Peer-Reviewed Original ResearchConceptsHigh-dose influenza vaccinationPlasma cell dyscrasiaInfluenza vaccinationProtective immunityCell dyscrasiaPCD patientsPlacebo-controlled clinical trialHigh-dose vaccinationHigh-dose vaccineInfluenza-specific immunityBurden of influenzaSaline placebo injectionsAge-based vaccinationHigher seroprotectionSerologic immunityPlacebo injectionsVaccine strategiesTiter responseClinical trialsFlu seasonPatientsVaccinationImmunityNovel coronavirusSeroprotection